CLINICAL_TRIALS
trial_result
· 2024-05-03
Clinical Trial Update: Study of Adjuvant ONO-4538 With Resected Gastric Cancer [Phase 3]
Summary
Phase 3 trial evaluating adjuvant ONO-4538 (nivolumab) after gastric cancer resection has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Gastric Cancer | Phase 3 | Status: COMPLETED